Your browser doesn't support javascript.
loading
Cholesterol not particle concentration mediates the atherogenic risk conferred by apolipoprotein B particles: a Mendelian randomization analysis.
Helgadottir, Anna; Thorleifsson, Gudmar; Snaebjarnarson, Audunn; Stefansdottir, Lilja; Sveinbjornsson, Gardar; Tragante, Vinicius; Björnsson, Eyþór; Steinthorsdottir, Valgerdur; Gretarsdottir, Solveig; Helgason, Hannes; Saemundsdottir, Jona; Olafsson, Isleifur; Thune, Jens Jakob; Raja, Anna Axelsson; Ghouse, Jonas; Olesen, Morten Salling; Christensen, Alex; Jacobsen, Rikke Louise; Dowsett, Joseph; Bruun, Mie Topholm; Nielsen, Kaspar; Knowlton, Kirk; Nadauld, Lincoln; Benediktsson, Rafn; Erikstrup, Christian; Pedersen, Ole B; Banasik, Karina; Brunak, Søren; Bundgaard, Henning; Ostrowski, Sisse R; Sulem, Patrick; Arnar, David O; Thorgeirsson, Gudmundur; Thorsteinsdottir, Unnur; Gudbjartsson, Daniel F; Stefansson, Kari; Holm, Hilma.
Afiliação
  • Helgadottir A; deCODE Genetics/Amgen, Inc., Sturlugata 8, Reykjavik 101, Iceland.
  • Thorleifsson G; deCODE Genetics/Amgen, Inc., Sturlugata 8, Reykjavik 101, Iceland.
  • Snaebjarnarson A; deCODE Genetics/Amgen, Inc., Sturlugata 8, Reykjavik 101, Iceland.
  • Stefansdottir L; deCODE Genetics/Amgen, Inc., Sturlugata 8, Reykjavik 101, Iceland.
  • Sveinbjornsson G; deCODE Genetics/Amgen, Inc., Sturlugata 8, Reykjavik 101, Iceland.
  • Tragante V; deCODE Genetics/Amgen, Inc., Sturlugata 8, Reykjavik 101, Iceland.
  • Björnsson E; deCODE Genetics/Amgen, Inc., Sturlugata 8, Reykjavik 101, Iceland.
  • Steinthorsdottir V; deCODE Genetics/Amgen, Inc., Sturlugata 8, Reykjavik 101, Iceland.
  • Gretarsdottir S; deCODE Genetics/Amgen, Inc., Sturlugata 8, Reykjavik 101, Iceland.
  • Helgason H; deCODE Genetics/Amgen, Inc., Sturlugata 8, Reykjavik 101, Iceland.
  • Saemundsdottir J; deCODE Genetics/Amgen, Inc., Sturlugata 8, Reykjavik 101, Iceland.
  • Olafsson I; Department of Clinical Biochemistry, Landspitali - The National University Hospital of Iceland, Reykjavik 101, Iceland.
  • Thune JJ; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Raja AA; Department of Cardiology, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark.
  • Ghouse J; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Olesen MS; Department of Cardiology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
  • Christensen A; Laboratory for Molecular Cardiology, Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
  • Jacobsen RL; Laboratory for Molecular Cardiology, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Dowsett J; Laboratory for Molecular Cardiology, Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
  • Bruun MT; Laboratory for Molecular Cardiology, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Nielsen K; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Knowlton K; Department of Cardiology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
  • Nadauld L; Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
  • Benediktsson R; Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
  • Erikstrup C; Department of Clinical Immunology, Odense University Hospital, Odense, Denmark.
  • Pedersen OB; Department of Clicnical Immunology, Aalborg University Hospital, Aalborg, Denmark.
  • Banasik K; Intermountain Healthcare, Salt Lake City, UT, USA.
  • Brunak S; Intermountain Healthcare, St. George, UT, USA.
  • Bundgaard H; Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark.
  • Ostrowski SR; Department of Clinical Immunology, Zealand University Hospital-Køge, Køge, Denmark.
  • Sulem P; Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Arnar DO; Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Thorsteinsdottir U; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Gudbjartsson DF; Department of Cardiology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
  • Stefansson K; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Holm H; Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Eur J Prev Cardiol ; 29(18): 2374-2385, 2022 12 21.
Article em En | MEDLINE | ID: mdl-36125206
ABSTRACT
BACKGROUND AND

AIMS:

The causal contribution of apolipoprotein B (apoB) particles to coronary artery disease (CAD) is established. We examined whether this atherogenic contribution is better reflected by non-high-density lipoprotein cholesterol (non-HDL-C) or apoB particle concentration. METHOD AND

RESULTS:

We performed Mendelian randomization (MR) analysis using 235 variants as genetic instruments; testing the relationship between their effects on the exposures, non-HDL-C and apoB, and on the outcome CAD using weighted regression. Variant effect estimates on the exposures came from the UK Biobank (N = 376 336) and on the outcome from a meta-analysis of five CAD datasets (187 451 cases and 793 315 controls). Subsequently, we carried out sensitivity and replication analyses.In univariate MR analysis, both exposures associated with CAD (ßnon-HDL-C = 0.40, P = 2.8 × 10-48 and ßapoB = 0.38, P = 1.3 × 10-44). Adding effects on non-HDL-C into a model that already included those on apoB significantly improved the genetically predicted CAD effects (P = 3.9 × 10-5), while adding apoB into the model including non-HDL-C did not (P = 0.69). Thirty-five per cent (82/235) of the variants used as genetic instruments had discordant effects on the exposures, associating with non-HDL-C/apoB ratio at P < 2.1 × 10-4 (0.05/235). Fifty-one variants associated at genome-wide significance.

CONCLUSION:

Many sequence variants have discordant effects on non-HDL-C and apoB. These variants allowed us to show that the causal mechanism underlying the relationship between apolipoprotein B particles and CAD is more associated with non-HDL-C than apoB particle concentration.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença da Artéria Coronariana / Aterosclerose Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença da Artéria Coronariana / Aterosclerose Idioma: En Ano de publicação: 2022 Tipo de documento: Article